NCT03239223View on ClinicalTrials.gov

Study of Topical ABI-1968 in Subjects With Precancerous Cervical Lesions From Human Papillomavirus (HPV) Infection

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

January 1, 2018

Primary Completion Date

October 30, 2018

Study Completion Date

October 30, 2018

Conditions
HSILHSIL of CervixHigh-Grade Squamous Intraepithelial LesionsHigh-grade Cervical Intraepithelial NeoplasiaHuman Papilloma VirusCervical CancerCervical Intraepithelial NeoplasiaCervical NeoplasmCervical DysplasiaCIN
Interventions
DRUG

ABI-1968

Topical ABI-1968 Cream or Placebo with 4 doses administered up to 4 Cohorts

Trial Locations (9)

2010

Research Center, Darlinghurst

2050

Research Center, Camperdown

4101

Research Center, South Brisbane

27101

Research Center, Winston-Salem

27517

Research Center, Chapel Hill

33461

Research Center, Lake Worth

83404

Research Center, Idaho Falls

84304

Research Center, Norfolk

90036

Research Center, Los Angeles

Sponsors

Lead Sponsor

Antiva Biosciences
All Listed Sponsors
lead

Antiva Biosciences

INDUSTRY

NCT03239223 - Study of Topical ABI-1968 in Subjects With Precancerous Cervical Lesions From Human Papillomavirus (HPV) Infection | Biotech Hunter | Biotech Hunter